Atossa advances oral SERM/SERD (Z)-Endoxifen with资本市场 update
Atossa reported $26.1M in cash after dosing ~800 patients in two FDA priority review programs. It seeks a potential best-in-class oral therapy for estrogen-driven diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed